Drug intelligence / Profile preview

IVACFLU-S

Development stage: Phase 3
Lead developer: Institute of Vaccines and Medical Biologicals
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

IVACFLU-S is a seasonal, trivalent, inactivated, split virion influenza vaccine developed in Vietnam. It contains three influenza strains (A/H1N1, A/H3N2, and B) grown in embryonated chicken eggs. The vaccine was developed under the WHO's Global Action Plan for influenza vaccines through collaboration between the Institute of Vaccines and Medical Biologicals (IVAC) in Vietnam and the Program for Appropriate Technology in Health (PATH). Clinical trials have demonstrated that IVACFLU-S is safe, well-tolerated, and induces strong immune responses in adults aged 18-60 years.

Beyond the preview

Go deeper on IVACFLU-S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVACFLU-S.

Explore the full profile